UTAC®

Shuttling Monoclonal Antibodies from Pill to Bloodstream

The “Holy Grail” of Drug Delivery

Enhances systemic exposure of mAbs, PoC PK/transport biology established in NHPs

Reversible, non-covalent binding releases cargo antibodies intact, with no re-engineering required

Wide applicability across biologics including antibodies, peptides, and proteins

Co-formulated in pill format and fully compatible with Soteria® and Duocoat®

UTAC® (Universal Transcytosis of Active Cargo) is a novel platform technology designed to enhance systemic uptake of monoclonal antibodies and other biopharmaceutical drugs from the gut via the oral route. UTAC® bispecifics bind monoclonal antibodies in a non-covalent, reversible manner and then co-opt a natural transport process in order to shuttle these antibodies across the epithelial single-cell barrier that lines the gut. Once a UTAC® bispecific has transported the antibody across the epithelial cell, it releases the antibody into the tissue and onward into the systemic blood circulation. UTAC® bispecifics are co-formulated with cargo antibody in pill format. UTAC® works seamlessly with Intract’s protease-protection Soteria® and rapid-release Duocoat® technologies. Together, this triad of proprietary Intract technologies maximises oral monoclonal antibody systemic uptake, addressing the holy grail in biologics delivery.